Pfizer's Diverse Portfolio And Strong Execution Earn Analyst Praise Despite Patent Concerns

On Tuesday, Pfizer Inc. PFE reported second-quarter adjusted EPS of $0.60, down 11% year over year, beating the consensus of $0.46.The U.S. drugmaker reported sales of $13.28 billion, up 2% year-over-year (up 3% operationally), beating the consensus of $13.02 billion.Truist Securities sees the strong demand growth as highly encouraging and, at current levels, Pfizer shares are very attractive given the company’s diverse portfolio that is gaining momentum, effective cost-cutting initiatives, and a commitment ...